ArticleRheumatology (Oxford, England)2026
Mortality and causes of death in patients with Sjögren disease in Western Australia: a population-based study.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesSjögren disease (SjD) is a systemic autoimmune disorder with emerging evidence showing increased mortality rates compared with the general population. We compared mortality risk and causes of death in Western Australian (WA) SjD patients with age/sex-matched controls and general population mortality rates.
methodsThe WA Rheumatic Disease Epidemiological Registry (WARDER) was accessed in this data linkage study to identify patients with primary SjD, SjD associated with rheumatoid arthritis (SjD + RA) and SjD associated with other connective tissue disease (SjD + CTD) using ICD codes and age/sex matched controls (1:5) between 1980 and 2013. Mortality of SjD cohorts was compared with both age/sex-matched controls from WA and population mortality rates. Multiple cause of death and competing risk analysis was performed for SjD cohorts compared with controls.
resultsA total of 3716 controls (1345 deaths) were compared with 457 primary SjD (204 deaths), 218 SjD + RA (149 deaths) and 77 SjD + CTD (38 deaths). Risk of mortality was increased in primary SjD [HR 1.8 (95% CI 1.5, 2.0)] and in associated SjD {SjD + RA: HR 2.1 [95% CI (1.8, 2.5)]; SjD + CTD: HR 3.1 (95% CI 2.2, 4.3)} compared with controls. Survival in primary SjD was 77% (95% CI 0.63, 0.94) at the end of follow-up (25 years). Mortality risk in primary and associated SjD was increased due to infection, ischaemic heart disease, lymphoid malignancy and interstitial lung disease.
conclusionAll-cause and specific-cause mortality was increased in primary and associated SjD compared with age/sex-matched controls in an Australian population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.